JP2012524725A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524725A5
JP2012524725A5 JP2012506297A JP2012506297A JP2012524725A5 JP 2012524725 A5 JP2012524725 A5 JP 2012524725A5 JP 2012506297 A JP2012506297 A JP 2012506297A JP 2012506297 A JP2012506297 A JP 2012506297A JP 2012524725 A5 JP2012524725 A5 JP 2012524725A5
Authority
JP
Japan
Prior art keywords
klk1
seq
pharmaceutical composition
polypeptide
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524725A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/000575 external-priority patent/WO2010121361A1/en
Publication of JP2012524725A publication Critical patent/JP2012524725A/ja
Publication of JP2012524725A5 publication Critical patent/JP2012524725A5/ja
Pending legal-status Critical Current

Links

JP2012506297A 2009-04-22 2010-04-22 ハンチントン病を治療するための組織カリクレイン Pending JP2012524725A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17157909P 2009-04-22 2009-04-22
US61/171,579 2009-04-22
PCT/CA2010/000575 WO2010121361A1 (en) 2009-04-22 2010-04-22 Tissue kallikrein for the treatment of huntington's disease

Publications (2)

Publication Number Publication Date
JP2012524725A JP2012524725A (ja) 2012-10-18
JP2012524725A5 true JP2012524725A5 (enExample) 2013-05-30

Family

ID=43010630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506297A Pending JP2012524725A (ja) 2009-04-22 2010-04-22 ハンチントン病を治療するための組織カリクレイン

Country Status (6)

Country Link
US (1) US20120225051A1 (enExample)
EP (1) EP2421554A4 (enExample)
JP (1) JP2012524725A (enExample)
CN (1) CN102458454A (enExample)
CA (1) CA2759490A1 (enExample)
WO (1) WO2010121361A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501695B2 (en) 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
US20130315891A1 (en) * 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
CA2880085C (en) 2012-06-04 2021-09-07 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2015109107A1 (en) * 2014-01-15 2015-07-23 Cal Poly Pomona Foundation, Inc. Treatment and diagnosis of huntington's disease
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. TISSUE KALLICREIN DOSAGE FORMS 1
CN116549619A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056532A2 (en) * 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
EP1664790A2 (en) * 2003-08-30 2006-06-07 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005022146A2 (en) * 2003-08-30 2005-03-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
US8501695B2 (en) * 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein

Similar Documents

Publication Publication Date Title
ES2661500T3 (es) Variantes de HMGB1 y sus usos
JP2014526441A5 (enExample)
JP2012524725A5 (enExample)
CN103476933B (zh) 白介素1受体的拮抗剂
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
McLane et al. Disintegrins in health and disease
NZ602824A (en) Sparc binding peptides and uses thereof
MX2012015000A (es) Nuevo peptido y uso del mismo.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2012530073A5 (enExample)
JP2015512927A5 (enExample)
HRP20161560T1 (hr) Varijanta, rekombinantnih proteina beta-glukocerebrozidaze s povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću
JP2006506942A5 (enExample)
AU2015336008B2 (en) Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
JP2009505979A5 (enExample)
US12214024B2 (en) Use of APC analogue for wound healing
AU2012268078B2 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
JP2007521333A5 (enExample)
JP2014515595A5 (enExample)
JP2015528460A (ja) インクレチンホルモン又はそのアナログを用いた変形性関節症の処置
JP2014512369A5 (enExample)
AU2019202876B2 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
WO2012027170A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
KR101645015B1 (ko) Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물
Huang et al. Efficacy of granulocyte-colony stimulating factor treatment in a rat model of anterior ischemic optic neuropathy